{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:02:38Z","timestamp":1790953358597,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2022YFS0376"],"award-info":[{"award-number":["2022YFS0376"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10549-022-06627-y","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T11:03:01Z","timestamp":1654513381000},"page":"279-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses"],"prefix":"10.1007","volume":"194","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjie","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4822-4471","authenticated-orcid":false,"given":"Zhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"6627_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2007.10.009","volume":"44","author":"EA Rakha","year":"2008","unstructured":"Rakha EA, El-Sayed ME, Powe DG et al (2008) Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 44:73\u201383. https:\/\/doi.org\/10.1016\/j.ejca.2007.10.009","journal-title":"Eur J Cancer"},{"key":"6627_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10549-008-0112-4","volume":"117","author":"G Viale","year":"2009","unstructured":"Viale G, Rotmensz N, Maisonneuve P et al (2009) Lack of prognostic significance of \u201cclassic\u201d lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat 117:211\u2013214. https:\/\/doi.org\/10.1007\/s10549-008-0112-4","journal-title":"Breast Cancer Res Treat"},{"key":"6627_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10549-007-9768-4","volume":"111","author":"EA Rakha","year":"2008","unstructured":"Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH, Ellis IO (2008) Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 111:121\u2013127. https:\/\/doi.org\/10.1007\/s10549-007-9768-4","journal-title":"Breast Cancer Res Treat"},{"key":"6627_CR4","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/cncr.23811","volume":"113","author":"E Orvieto","year":"2008","unstructured":"Orvieto E, Maiorano E, Bottiglieri L et al (2008) Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 113:1511\u20131520. https:\/\/doi.org\/10.1002\/cncr.23811","journal-title":"Cancer"},{"key":"6627_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/02841860601137397","volume":"46","author":"ML Talman","year":"2007","unstructured":"Talman ML, Jensen MB, Rank F (2007) Invasive lobular breast cancer. Prognostic significance of histological malignancy grading. Acta Oncol 46:803\u2013809. https:\/\/doi.org\/10.1080\/02841860601137397","journal-title":"Acta Oncol"},{"key":"6627_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/0046-8177(92)90321-s","volume":"23","author":"V Eusebi","year":"1992","unstructured":"Eusebi V, Magalhaes F, Azzopardi JG (1992) Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 23:655\u2013662. https:\/\/doi.org\/10.1016\/0046-8177(92)90321-s","journal-title":"Hum Pathol"},{"key":"6627_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05606-5","volume":"181","author":"RA Mukhtar","year":"2020","unstructured":"Mukhtar RA, Krings G, Chen YY et al (2020) Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival. Breast Cancer Res Treat 181:23\u201329. https:\/\/doi.org\/10.1007\/s10549-020-05606-5","journal-title":"Breast Cancer Res Treat"},{"key":"6627_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/01.MP.0000073974.42583.F7","volume":"16","author":"J Palacios","year":"2003","unstructured":"Palacios J, Sarri\u00f3 D, Garc\u00eda-Macias MC, Bryant B, Sobel ME, Merino MJ (2003) Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod Pathol 16:674\u2013678. https:\/\/doi.org\/10.1097\/01.MP.0000073974.42583.F7","journal-title":"Mod Pathol"},{"key":"6627_CR9","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1200\/JCO.2015.64.0334","volume":"34","author":"C Desmedt","year":"2016","unstructured":"Desmedt C, Zoppoli G, Gundem G et al (2016) Genomic characterization of primary invasive lobular breast cancer. J Clin Oncol 34:1872\u20131881. https:\/\/doi.org\/10.1200\/JCO.2015.64.0334","journal-title":"J Clin Oncol"},{"key":"6627_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/path.1806","volume":"207","author":"JS Reis-Filho","year":"2005","unstructured":"Reis-Filho JS, Simpson PT, Jones C et al (2005) Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 207:1\u201313. https:\/\/doi.org\/10.1002\/path.1806","journal-title":"J Pathol"},{"key":"6627_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/path.2358","volume":"215","author":"PT Simpson","year":"2008","unstructured":"Simpson PT, Reis-Filho JS, Lambros MB et al (2008) Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 215:231\u2013244. https:\/\/doi.org\/10.1002\/path.2358","journal-title":"J Pathol"},{"key":"6627_CR12","first-page":"116","volume-title":"WHO classification of tumours editorial board","author":"KH Allison","year":"2019","unstructured":"Allison KH, Brogi E, Ellis IO et al (2019) WHO classification of tumours editorial board. Breast Tumours. International Agency for Research on Cancer, Lyon, pp 116\u2013117"},{"key":"6627_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/jso.21121","volume":"98","author":"CL Buchanan","year":"2008","unstructured":"Buchanan CL, Flynn LW, Murray MP et al (2008) Is pleomorphic lobular carcinoma really a distinct clinical entity? J Surg Oncol 98:314\u2013317. https:\/\/doi.org\/10.1002\/jso.21121","journal-title":"J Surg Oncol"},{"key":"6627_CR14","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.5858\/arpa.2012-0603-RS","volume":"137","author":"D Butler","year":"2013","unstructured":"Butler D, Rosa M (2013) Pleomorphic lobular carcinoma of the breast: a morphologically and clinically distinct variant of lobular carcinoma. Arch Pathol Lab Med 137:1688\u20131692. https:\/\/doi.org\/10.5858\/arpa.2012-0603-RS","journal-title":"Arch Pathol Lab Med"},{"key":"6627_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.clbc.2017.06.006","volume":"18","author":"YL Liu","year":"2018","unstructured":"Liu YL, Choi C, Lee SM et al (2018) Invasive lobular breast carcinoma: pleomorphic versus classical subtype, associations and prognosis. Clin Breast Cancer 18:114\u2013120. https:\/\/doi.org\/10.1016\/j.clbc.2017.06.006","journal-title":"Clin Breast Cancer"},{"key":"6627_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.breast.2018.11.007","volume":"43","author":"W Haque","year":"2019","unstructured":"Haque W, Arms A, Verma V, Hatch S, Brian Butler E, Teh BS (2019) Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma. Breast 43:67\u201373. https:\/\/doi.org\/10.1016\/j.breast.2018.11.007","journal-title":"Breast"},{"key":"6627_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.anndiagpath.2015.01.005","volume":"19","author":"S Narendra","year":"2015","unstructured":"Narendra S, Jenkins SM, Khoor A, Nassar A (2015) Clinical outcome in pleomorphic lobular carcinoma: a case-control study with comparison to classic invasive lobular carcinoma. Ann Diagn Pathol 19:64\u201369. https:\/\/doi.org\/10.1016\/j.anndiagpath.2015.01.005","journal-title":"Ann Diagn Pathol"},{"key":"6627_CR18","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: breast cancer. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/breast-invasive-patient.pdf. Accessed 26 June 2021"},{"key":"6627_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s10549-012-2002-z","volume":"133","author":"M Iorfida","year":"2012","unstructured":"Iorfida M, Maiorano E, Orvieto E et al (2012) Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 133:713\u2013723. https:\/\/doi.org\/10.1007\/s10549-012-2002-z","journal-title":"Breast Cancer Res Treat"},{"key":"6627_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/cyt.12362","volume":"28","author":"R Ohashi","year":"2017","unstructured":"Ohashi R, Matsubara M, Watarai Y et al (2017) Pleomorphic lobular carcinoma of the breast: a comparison of cytopathological features with other lobular carcinoma variants. Cytopathology 28:122\u2013130. https:\/\/doi.org\/10.1111\/cyt.12362","journal-title":"Cytopathology"},{"key":"6627_CR21","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/s41379-020-0561-9","volume":"33","author":"JC Tille","year":"2020","unstructured":"Tille JC, Vieira AF, Saint-Martin C et al (2020) Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Mod Pathol 33:2198\u20132207. https:\/\/doi.org\/10.1038\/s41379-020-0561-9","journal-title":"Mod Pathol"},{"key":"6627_CR22","first-page":"861","volume-title":"Rosen's breast pathology-fourth edition","author":"SA Hoda","year":"2014","unstructured":"Hoda SA, Brogi E, Koerner FC, Rosen PP (2014) Rosen\u2019s breast pathology-fourth edition. Wolters Kluwer Health, Lippincott Williams & Wilkins, Philadelphia, pp 861\u2013866"},{"key":"6627_CR23","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105\u20132122. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"6627_CR24","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02\u201398. J Clin Oncol 31:860\u2013867. https:\/\/doi.org\/10.1200\/JCO.2011.41.0902","journal-title":"J Clin Oncol"},{"key":"6627_CR25","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959\u20132966. https:\/\/doi.org\/10.1200\/JCO.2013.55.0491","journal-title":"J Clin Oncol"},{"key":"6627_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1440-1827.1998.tb03917.x","volume":"48","author":"L Fu","year":"1998","unstructured":"Fu L, Tsuchiya S, Matsuyama I, Ishii K (1998) Clinicopathologic features and incidence of invasive lobular carcinoma in Japanese women. Pathol Int 48:348\u2013354. https:\/\/doi.org\/10.1111\/j.1440-1827.1998.tb03917.x","journal-title":"Pathol Int"},{"key":"6627_CR27","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1245\/s10434-011-1626-2","volume":"18","author":"S Li","year":"2011","unstructured":"Li S, Yu KD, Fan L, Hou YF, Shao ZM (2011) Predicting breast cancer recurrence following breast-conserving therapy: a single-institution analysis consisting of 764 Chinese breast cancer cases. Ann Surg Oncol 18:2492\u20132499. https:\/\/doi.org\/10.1245\/s10434-011-1626-2","journal-title":"Ann Surg Oncol"},{"key":"6627_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10549-020-05861-6","volume":"184","author":"J Kim","year":"2020","unstructured":"Kim J, Kim JY, Lee HB et al (2020) Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type. Breast Cancer Res Treat 184:527\u2013542. https:\/\/doi.org\/10.1007\/s10549-020-05861-6","journal-title":"Breast Cancer Res Treat"},{"key":"6627_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.clbc.2015.06.010","volume":"15","author":"K Al-Baimani","year":"2015","unstructured":"Al-Baimani K, Bazzarelli A, Clemons M, Robertson SJ, Addison C, Arnaout A (2015) Invasive pleomorphic lobular carcinoma of the breast: pathologic, clinical, and therapeutic considerations. Clin Breast Cancer 15:421\u2013425. https:\/\/doi.org\/10.1016\/j.clbc.2015.06.010","journal-title":"Clin Breast Cancer"},{"key":"6627_CR30","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.breast.2012.07.016","volume":"22","author":"HN Jung","year":"2013","unstructured":"Jung HN, Shin JH, Han BK, Ko EY, Cho EY (2013) Are the imaging features of the pleomorphic variant of invasive lobular carcinoma different from classic ILC of the breast? Breast 22:324\u2013329. https:\/\/doi.org\/10.1016\/j.breast.2012.07.016","journal-title":"Breast"},{"key":"6627_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2559.2012.04230.x","volume":"61","author":"L Monhollen","year":"2012","unstructured":"Monhollen L, Morrison C, Ademuyiwa FO, Chandrasekhar R, Khoury T (2012) Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type. Histopathology 61:365\u2013377. https:\/\/doi.org\/10.1111\/j.1365-2559.2012.04230.x","journal-title":"Histopathology"},{"key":"6627_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/modpathol.2012.197","volume":"26","author":"EA Rakha","year":"2013","unstructured":"Rakha EA, van Deurzen CH, Paish EC, Macmillan RD, Ellis IO, Lee AH (2013) Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade? Mod Pathol 26:496\u2013501. https:\/\/doi.org\/10.1038\/modpathol.2012.197","journal-title":"Mod Pathol"},{"key":"6627_CR33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-015-3336-0","volume":"150","author":"HC Lien","year":"2015","unstructured":"Lien HC, Chen YL, Juang YL, Jeng YM (2015) Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast. Breast Cancer Res Treat 150:447\u2013455. https:\/\/doi.org\/10.1007\/s10549-015-3336-0","journal-title":"Breast Cancer Res Treat"},{"key":"6627_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/jclinpath-2018-205485","volume":"72","author":"C D'Arcy","year":"2019","unstructured":"D\u2019Arcy C, Quinn CM (2019) Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast. J Clin Pathol 72:7\u201311. https:\/\/doi.org\/10.1136\/jclinpath-2018-205485","journal-title":"J Clin Pathol"},{"key":"6627_CR35","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1245\/s10434-021-10518-9","volume":"28","author":"A Saridakis","year":"2021","unstructured":"Saridakis A, Berger ER, Harigopal M et al (2021) Apocrine breast cancer: unique features of a predominantly triple-negative breast cancer. Ann Surg Oncol 28:5610\u20135616. https:\/\/doi.org\/10.1245\/s10434-021-10518-9","journal-title":"Ann Surg Oncol"},{"key":"6627_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/PAS.0000000000001341","volume":"44","author":"LK Clinton","year":"2020","unstructured":"Clinton LK, Plesec T, Goldblum JR, Hajifathalian K, Downs-Kelly E, Patil DT (2020) Specific histopathologic features aid in distinguishing diffuse-type gastric adenocarcinoma from metastatic lobular breast carcinoma. Am J Surg Pathol 44:77\u201386. https:\/\/doi.org\/10.1097\/PAS.0000000000001341","journal-title":"Am J Surg Pathol"},{"key":"6627_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/jamasurg.2021.5118","volume":"157","author":"LA Gamble","year":"2022","unstructured":"Gamble LA, Rossi A, Fasaye GA et al (2022) Association between hereditary lobular breast cancer due to CDH1 variants and gastric cancer risk. JAMA Surg 157:18\u201322. https:\/\/doi.org\/10.1001\/jamasurg.2021.5118","journal-title":"JAMA Surg"},{"key":"6627_CR38","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/s41379-021-00742-9","volume":"34","author":"A Bergeron","year":"2021","unstructured":"Bergeron A, MacGrogan G, Bertaut A et al (2021) Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. Mod Pathol 34:1282\u20131296. https:\/\/doi.org\/10.1038\/s41379-021-00742-9","journal-title":"Mod Pathol"},{"key":"6627_CR39","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/PAS.0000000000001493","volume":"44","author":"E Zhong","year":"2020","unstructured":"Zhong E, Solomon JP, Cheng E, Baum J, Song W, Hoda SA (2020) Apocrine variant of pleomorphic lobular carcinoma in situ: further clinical, histopathologic, immunohistochemical, and molecular characterization of an emerging entity. Am J Surg Pathol 44:1092\u20131103. https:\/\/doi.org\/10.1097\/PAS.0000000000001493","journal-title":"Am J Surg Pathol"},{"key":"6627_CR40","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s41379-020-00692-8","volume":"34","author":"D Ai","year":"2021","unstructured":"Ai D, Yao J, Yang F et al (2021) TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34:710\u2013719. https:\/\/doi.org\/10.1038\/s41379-020-00692-8","journal-title":"Mod Pathol"},{"key":"6627_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.humpath.2018.11.005","volume":"85","author":"GH Tozbikian","year":"2019","unstructured":"Tozbikian GH, Zynger DL (2019) A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer. Hum Pathol 85:221\u2013227. https:\/\/doi.org\/10.1016\/j.humpath.2018.11.005","journal-title":"Hum Pathol"},{"key":"6627_CR42","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1349-7006.1997.tb00423.x","volume":"88","author":"T Hasebe","year":"1997","unstructured":"Hasebe T, Tsuda H, Tsubono Y, Imoto S, Mukai K (1997) Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation. Jpn J Cancer Res 88:590\u2013599. https:\/\/doi.org\/10.1111\/j.1349-7006.1997.tb00423.x","journal-title":"Jpn J Cancer Res"},{"key":"6627_CR43","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi S, Michiels S, Salgado R et al (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:1544\u20131550. https:\/\/doi.org\/10.1093\/annonc\/mdu112","journal-title":"Ann Oncol"},{"key":"6627_CR44","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S et al (2019) Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 37:559\u2013569. https:\/\/doi.org\/10.1200\/JCO.18.01010","journal-title":"J Clin Oncol"},{"key":"6627_CR45","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/jnci\/djx268","volume":"110","author":"C Desmedt","year":"2018","unstructured":"Desmedt C, Salgado R, Fornili M et al (2018) Immune infiltration in invasive lobular breast cancer. J Natl Cancer Inst 110:768\u2013776. https:\/\/doi.org\/10.1093\/jnci\/djx268","journal-title":"J Natl Cancer Inst"},{"key":"6627_CR46","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","volume":"1","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Campbell C et al (2015) Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol 1:448\u2013454. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0830","journal-title":"JAMA Oncol"},{"key":"6627_CR47","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.2214\/AJR.13.11156","volume":"202","author":"H He","year":"2014","unstructured":"He H, Gonzalez A, Robinson E, Yang WT (2014) Distant metastatic disease manifestations in infiltrating lobular carcinoma of the breast. AJR Am J Roentgenol 202:1140\u20131148. https:\/\/doi.org\/10.2214\/AJR.13.11156","journal-title":"AJR Am J Roentgenol"},{"key":"6627_CR48","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/j.clbc.2017.07.003","volume":"18","author":"E Montagna","year":"2018","unstructured":"Montagna E, Pirola S, Maisonneuve P et al (2018) Lobular metastatic breast cancer patients with gastrointestinal involvement: features and outcomes. Clin Breast Cancer 18:e401\u2013e405. https:\/\/doi.org\/10.1016\/j.clbc.2017.07.003","journal-title":"Clin Breast Cancer"},{"key":"6627_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13058-020-01324-4","volume":"22","author":"S Kurozumi","year":"2020","unstructured":"Kurozumi S, Alsaleem M, Monteiro CJ et al (2020) Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Res 22:85. https:\/\/doi.org\/10.1186\/s13058-020-01324-4","journal-title":"Breast Cancer Res"},{"key":"6627_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13058-020-01385-5","volume":"23","author":"GM Riedlinger","year":"2021","unstructured":"Riedlinger GM, Joshi S, Hirshfield KM, Barnard N, Ganesan S (2021) Targetable alterations in invasive pleomorphic lobular carcinoma of the breast. Breast Cancer Res 23:7. https:\/\/doi.org\/10.1186\/s13058-020-01385-5","journal-title":"Breast Cancer Res"},{"key":"6627_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/cancers11010074","volume":"11","author":"JM Rosa-Rosa","year":"2019","unstructured":"Rosa-Rosa JM, Caniego-Casas T, Leskela S et al (2019) High frequency of ERBB2 activating mutations in invasive lobular breast carcinoma with pleomorphic features. Cancers (Basel) 11:74. https:\/\/doi.org\/10.3390\/cancers11010074","journal-title":"Cancers (Basel)"},{"key":"6627_CR52","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.97398","volume":"3","author":"S Zhu","year":"2018","unstructured":"Zhu S, Ward BM, Yu J et al (2018) IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma. JCI Insight 3:e97398. https:\/\/doi.org\/10.1172\/jci.insight.97398","journal-title":"JCI Insight"},{"key":"6627_CR53","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3390\/curroncol28030150","volume":"28","author":"L He","year":"2021","unstructured":"He L, Araj E, Peng Y (2021) HER2 positive and HER2 negative classical type invasive lobular carcinomas: comparison of clinicopathologic features. Curr Oncol 28:1608\u20131617. https:\/\/doi.org\/10.3390\/curroncol28030150","journal-title":"Curr Oncol"},{"key":"6627_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153441","volume":"222","author":"C LaBoy","year":"2021","unstructured":"LaBoy C, Siziopikou KP, Rosen L, Blanco LZ Jr, Pincus JL (2021) Clinicopathologic features of unexpectedly HER2 positive breast carcinomas: an institutional experience. Pathol Res Pract 222:153441. https:\/\/doi.org\/10.1016\/j.prp.2021.153441","journal-title":"Pathol Res Pract"},{"key":"6627_CR55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s13402-012-0071-y","volume":"35","author":"C Ercan","year":"2012","unstructured":"Ercan C, van Diest PJ, van der Ende B et al (2012) p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast. Cell Oncol (Dordr) 35:111\u2013118. https:\/\/doi.org\/10.1007\/s13402-012-0071-y","journal-title":"Cell Oncol (Dordr)"},{"key":"6627_CR56","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.celrep.2016.08.048","volume":"16","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, Christin JR, Wang C, Ge K, Oktay MH, Guo W (2016) Mammary-stem-cell-based somatic mouse models reveal breast cancer drivers causing cell fate dysregulation. Cell Rep 16:3146\u20133156. https:\/\/doi.org\/10.1016\/j.celrep.2016.08.048","journal-title":"Cell Rep"},{"key":"6627_CR57","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244:707\u2013712. https:\/\/doi.org\/10.1126\/science.2470152","journal-title":"Science"},{"key":"6627_CR58","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/GCO.0000000000000038","volume":"26","author":"KM Hirshfield","year":"2014","unstructured":"Hirshfield KM, Ganesan S (2014) Triple-negative breast cancer: molecular subtypes and targeted therapy. Curr Opin Obstet Gynecol 26:34\u201340. https:\/\/doi.org\/10.1097\/GCO.0000000000000038","journal-title":"Curr Opin Obstet Gynecol"},{"key":"6627_CR59","doi-asserted-by":"publisher","first-page":"8816824","DOI":"10.1155\/2020\/8816824","volume":"2020","author":"JM Segar","year":"2020","unstructured":"Segar JM, Pandey R, Farr KJ et al (2020) Clinicopathological and molecular characteristics of pleomorphic invasive lobular carcinoma. Int J Breast Cancer 2020:8816824. https:\/\/doi.org\/10.1155\/2020\/8816824","journal-title":"Int J Breast Cancer"},{"key":"6627_CR60","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1200\/JCO.2007.10.6393","volume":"26","author":"G Viale","year":"2008","unstructured":"Viale G, Regan MM, Maiorano E et al (2008) Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors\u2013International Breast Cancer Study Group. J Clin Oncol 26:1404\u20131410. https:\/\/doi.org\/10.1200\/JCO.2007.10.6393","journal-title":"J Clin Oncol"},{"key":"6627_CR61","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.1245\/s10434-021-09715-3","volume":"28","author":"RA Mukhtar","year":"2021","unstructured":"Mukhtar RA, Hoskin TL, Habermann EB, Day CN, Boughey JC (2021) Changes in management strategy and impact of neoadjuvant therapy on extent of surgery in invasive lobular carcinoma of the breast: analysis of the National Cancer Database (NCDB). Ann Surg Oncol 28:5867\u20135877. https:\/\/doi.org\/10.1245\/s10434-021-09715-3","journal-title":"Ann Surg Oncol"},{"key":"6627_CR62","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10549-019-05398-3","volume":"178","author":"SM Swain","year":"2019","unstructured":"Swain SM, Tang G, Lucas PC et al (2019) Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination. Breast Cancer Res Treat 178:389\u2013399. https:\/\/doi.org\/10.1007\/s10549-019-05398-3","journal-title":"Breast Cancer Res Treat"},{"key":"6627_CR63","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","volume":"70","author":"D Kwapisz","year":"2021","unstructured":"Kwapisz D (2021) Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother 70:607\u2013617. https:\/\/doi.org\/10.1007\/s00262-020-02736-z","journal-title":"Cancer Immunol Immunother"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06627-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06627-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06627-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T18:36:12Z","timestamp":1656441372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06627-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6627"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06627-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"15 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of West China Hospital (Date September 6, 2021 \/No 887).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}